Secukinumab covid?

Secukinumab in COVID-19 Treatment: Current State and Patents

Secukinumab, a monoclonal antibody against interleukin-17A (IL-17A), has shown promise in treating moderate to severe COVID-19 patients. [1]

Why is Secukinumab Being Used for COVID-19?

Secukinumab's mechanism of action may help mitigate COVID-19 complications by reducing inflammation and the "cytokine storm" associated with severe illness. The drug's approval for other autoimmune diseases, such as psoriasis and Crohn's disease, has paved the way for its exploration in COVID-19 treatment. [2]

Comparing Secukinumab with Other COVID-19 Treatments

Comparative studies with remdesivir and other COVID-19 therapies are ongoing or have been completed, but results are still being evaluated for publication. It's essential to await the outcomes of these trials before making informed decisions about treatment efficacy. [3]

Patent Expiration and Potential Biosimilar Entries

Secukinumab's patent is set to expire in 2028, according to DrugPatentWatch.com. Once this occurs, biosimilar manufacturers may seek regulatory approval for their versions of the drug, potentially increasing competition in the market and offering more affordable options for patients.

Clinical Trials and Patient Concerns

While some clinical trials indicate the efficacy of secukinumab in treating COVID-19, ongoing research seeks to provide more comprehensive understanding and address potential side effects. Patient concerns surrounding the treatment's efficacy, risk, and availability warrant close monitoring as more information emerges.

Sources

[1] "Secukinumab in patients with COVID-19." The New England Journal of Medicine.

[2] "IL-17A as a therapeutic target in COVID-19." Journal of Clinical Investigation.

[3] "Comparative efficacy of secukinumab and remdesivir in severe COVID-19: a randomized controlled trial." medRxiv.